<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN" "http://jats.nlm.nih.gov/publishing/1.1d3/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.1d3" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0158770</article-id>
<article-id pub-id-type="publisher-id">PONE-D-16-13232</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Mathematical and statistical techniques</subject><subj-group><subject>Statistical methods</subject><subj-group><subject>Meta-analysis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical sciences</subject><subj-group><subject>Mathematics</subject><subj-group><subject>Statistics (mathematics)</subject><subj-group><subject>Statistical methods</subject><subj-group><subject>Meta-analysis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and neoplasms</subject><subj-group><subject>Genitourinary tract tumors</subject><subj-group><subject>Prostate cancer</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Urology</subject><subj-group><subject>Prostate diseases</subject><subj-group><subject>Prostate cancer</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cellular types</subject><subj-group><subject>Animal cells</subject><subj-group><subject>Blood cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>T cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cellular types</subject><subj-group><subject>Animal cells</subject><subj-group><subject>Immune cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>T cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>T cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>T cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancer treatment</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Surgical and invasive medical procedures</subject><subj-group><subject>Reproductive system procedures</subject><subj-group><subject>Prostatectomy</subject><subj-group><subject>Radical prostatectomy</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Surgical and invasive medical procedures</subject><subj-group><subject>Surgical excision</subject><subj-group><subject>Prostatectomy</subject><subj-group><subject>Radical prostatectomy</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cellular types</subject><subj-group><subject>Animal cells</subject><subj-group><subject>Blood cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>Neutrophils</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cellular types</subject><subj-group><subject>Animal cells</subject><subj-group><subject>Immune cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>Neutrophils</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>Neutrophils</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>Neutrophils</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Exocrine glands</subject><subj-group><subject>Prostate gland</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Exocrine glands</subject><subj-group><subject>Prostate gland</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cellular types</subject><subj-group><subject>Animal cells</subject><subj-group><subject>Blood cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>Lymphocytes</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cellular types</subject><subj-group><subject>Animal cells</subject><subj-group><subject>Immune cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>Lymphocytes</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>Lymphocytes</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>Lymphocytes</subject></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Neutrophil-to-Lymphocyte Ratio Predicts PSA Response and Prognosis in Prostate Cancer: A Systematic Review and Meta-Analysis</article-title>
<alt-title alt-title-type="running-head">Neutrophil-to-Lymphocyte Ratio Predicts Prognosis in Prostate Cancer</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-7113-9267</contrib-id>
<name name-style="western">
<surname>Cao</surname>
<given-names>Jian</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
<name name-style="western">
<surname>Zhu</surname>
<given-names>Xuan</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Zhao</surname>
<given-names>Xiaokun</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Li</surname>
<given-names>Xue-Feng</given-names>
</name>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Xu</surname>
<given-names>Ran</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Department of Urology, The Second Xiangya Hospital, Central South University, Hunan Province, People’s Republic of China</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>MRC Centre for Reproductive Health, Queen’s Medical Research Institute, Edinburgh, United Kingdom</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Coleman</surname>
<given-names>William B.</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>University of North Carolina School of Medicine, UNITED STATES</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<fn fn-type="con" id="contrib001">
<p>Conceived and designed the experiments: RX XKZ. Performed the experiments: JC XZ. Analyzed the data: JC XFL XZ. Wrote the paper: JC XFL.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">ddf20@sina.com</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>1</day>
<month>7</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="collection">
<year>2016</year>
</pub-date>
<volume>11</volume>
<issue>7</issue>
<elocation-id>e0158770</elocation-id>
<history>
<date date-type="received">
<day>18</day>
<month>4</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>17</day>
<month>6</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-year>2016</copyright-year>
<copyright-holder>Cao et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pone.0158770"/>
<abstract>
<p>An unprecedented advance has been seen in castration-resistant prostate cancer (CRPC) treatments in the past few years. With a number of novel agents were approved, there is a pressing need to develop improved prognostic biomarkers to facilitate the personalised selection and sequencing of these novel agents. Emerging evidence indicates that the neutrophil-to-lymphocyte ratio (NLR) is associated with poorer survival in patients with prostate cancer (PCa). However, the importance of the NLR for the prediction of the PSA response (PSARS) and biochemical recurrence (BCR) has been largely neglected. Here, we conducted a systematic review and meta-analysis to evaluate the prognostic value of the NLR for the PSARS, BCR, and survival in PCa. A systematic database search was performed using Embase, PubMed, the Cochrane Library, and the China National Knowledge Infrastructure (CNKI). A meta-analysis was performed by pooling hazard ratios (HRs), odds ratios (ORs) and the corresponding 95% confidence intervals (CIs). A total of 22 studies were included in the meta-analysis. Our results suggest that an elevated NLR predicts a lower PSARS rate (OR = 1.69, 95% CI: 1.40–1.98) and a higher possibility of BCR (HR = 1.12, 95% CI: 1.02–1.21). Additionally, we confirmed that an elevated NLR was a prognostic predictor of shorter overall survival (OS) in both metastatic castration-resistant PCa (mCRPC) (HR = 1.45, 95% CI: 1.32–1.59) and localized PCa (LPC) (HR = 1.12, 95% CI: 1.01–1.23) and that it predicted worse progression-free survival (PFS) in CRPC (HR = 1.42, 95% CI: 1.23–1.61) and poorer recurrence-free survival (RFS) (HR = 1.38, 95%CI: 1.01–1.75) in LPC. Our results suggest that an elevated NLR might be employed as a prognostic marker of biochemical changes and prognosis to facilitate risk stratification and decision making for individual treatment of PCa patients. The potential mechanisms underlying these associations and future research directions are also discussed.</p>
</abstract>
<funding-group>
<award-group id="award001">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100004543</institution-id>
<institution>China Scholarship Council</institution>
</institution-wrap>
</funding-source>
<award-id>201506370137</award-id>
<principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-7113-9267</contrib-id>
<name name-style="western">
<surname>Cao</surname>
<given-names>Jian</given-names>
</name>
</principal-award-recipient>
</award-group>
<funding-statement>Jian Cao is sponsored by the China Scholarship Council (201506370137) as a visiting researcher in at the University of Edinburgh (<ext-link ext-link-type="uri" xlink:href="http://www.csc.edu.cn/" xlink:type="simple">http://www.csc.edu.cn/</ext-link>). The funder (China Scholarship Council) had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="3"/>
<table-count count="2"/>
<page-count count="15"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Introduction</title>
<p>Prostate cancer (PCa) is a major health concern for the male population; PCa is the second most common cancer and the fifth leading cause of cancer-associated death in men worldwide[<xref ref-type="bibr" rid="pone.0158770.ref001">1</xref>]. Although PCa-specific mortality in the US and the UK has declined markedly since the 1990s[<xref ref-type="bibr" rid="pone.0158770.ref002">2</xref>], slow increases and stable mortality have been observed in other regions[<xref ref-type="bibr" rid="pone.0158770.ref003">3</xref>]. A steady increase in the incidence rate was observed from 1975 to the early 1990s owing to the widespread application of transurethral resection and PSA testing for PCa screening[<xref ref-type="bibr" rid="pone.0158770.ref004">4</xref>,<xref ref-type="bibr" rid="pone.0158770.ref005">5</xref>]. This increase was followed by a stable incidence trend with an increased rate among patients younger than 70 years[<xref ref-type="bibr" rid="pone.0158770.ref006">6</xref>].</p>
<p>The PSA test was a landmark development in the early diagnosis of prostate cancer. Because PSA (a glycoprotein secreted by the prostate gland) is organ-derived and elevated PSA may also be caused by benign prostatic hypertrophy, prostatitis and recent manipulations of the prostate (massage, urethroscopy or biopsy), there is no precise threshold for a normal PSA value. However, higher PSA levels are thought to be indicative of a greater likelihood of PCa[<xref ref-type="bibr" rid="pone.0158770.ref007">7</xref>]. Some PSA-related testing parameters (e.g., PSA density, free/total PSA ratio, PSA doubling time, and prostate health index test) have been used to improve the accuracy of PCa prediction[<xref ref-type="bibr" rid="pone.0158770.ref007">7</xref>]. PSA is also important for monitoring biochemical recurrence (BCR) after radical therapies and managing metastatic disease[<xref ref-type="bibr" rid="pone.0158770.ref008">8</xref>].</p>
<p>With a number of new drugs have been approved for CRPC in the past few years, personalised drug selection and sequencing of agents has become more challenging. Therefore, prognostic biomarkers reflecting the response of this disease to these novel agents are needed to guide clinical management. The host inflammatory response plays a significant role in tumor progression[<xref ref-type="bibr" rid="pone.0158770.ref009">9</xref>]. Many parameters are utilized to determine the inflammatory response status of patients; the neutrophil-to-lymphocyte ratio (NLR) is the most commonly used because it is easily accessible. Many clinical studies have demonstrated that an increased NLR is correlated with poor prognosis in prostate cancer, and it also predicts PSA responses under different drug treatments. However, the results of these studies are inconsistent. A recent meta-analysis indicated that an elevated NLR was correlated with worse OS and PFS in mCRPC patients; however, this study did not consider biochemical changes in PCa[<xref ref-type="bibr" rid="pone.0158770.ref010">10</xref>]. To derive a more precise estimate of the prognostic significance of the NLR, in this study, we performed a systematic review of the most recently published studies. The importance of the NLR in predicting OS, PSARS and BCR in PCa were established using standard meta-analysis techniques.</p>
</sec>
<sec id="sec002" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="sec003">
<title>Search strategy</title>
<p>Systematic document retrieval was performed using PubMed, Embase, the Cochrane Library and China National Knowledge Infrastructure (CNKI) for all relevant studies without restrictions. To reduce heterogeneity, we also retrieved relevant studies written in Chinese from CNKI. Literature addressing the prognostic value of the NLR was searched by combining the following terms: (“neutrophil lymphocyte ratio” OR “neutrophil to lymphocyte ratio” OR “neutrophil-to-lymphocyte ratio” OR “NLR”) AND (“prostate neoplasm” OR “prostate carcinoma” OR “prostatic cancer” OR “prostatic neoplasm” OR “prostatic carcinoma”).</p>
<p>The last search was updated on February 11, 2016. The bibliographies of the relevant articles were also explored to identify any studies missed by the electronic search strategies. The search was independently conducted by two authors, and any discrepancies were resolved through group discussion and establishing a consensus.</p>
</sec>
<sec id="sec004">
<title>Study selection and data extraction</title>
<p>After the removal of duplicates, two independent reviewers (including one urologist) screened the titles, abstracts, and full texts of all related articles using established criteria. The inclusion criteria were as follows: (a) confirmed diagnosis of PCa based on pathological examination; (b) evaluation of the prognostic value of the pretreatment NLR in PCa; (c) reported association between the NLR and PCa prognosis; and (d) reported HR, OR and 95% CI for prognosis or inclusion of data sufficient to estimate these statistics. The exclusion criteria were as follows: (a) reviews, case reports, letters, editorials, and animal and in vitro studies; (b) studies without sufficient data; (c) studies that did not include specific prognostic data concerning the NLR; and (d) articles written in languages other than Chinese or English.</p>
<p>The data were extracted using a reporting checklist proposed by the Meta-analysis of Observational Studies in Epidemiology (MOOSE) Group[<xref ref-type="bibr" rid="pone.0158770.ref011">11</xref>]. The NLR value was calculated as the absolute neutrophil count divided by the absolute lymphocyte count obtained from a pre-treatment blood sample in all included studies. To date, there has been no validated cut-off value for NLR. In this meta-analysis, seven eligible studies defined elevated NLR as NLR≥5 and five studies used NLR≥3 as elevated NLR and two studies used NLR≥2, another two studies used NLR≥2.6 and ≥3.5 respectively. The BCR was defined as a PSA level ≥0.2 ng/ml in two consecutive tests. PSARS was defined as a PSA decline of ≥50% from baseline that was maintained for longer than 3 weeks. The HR, OR and 95% CI were obtained directly from each study or from reconstruction according to the methods described by Tierney et al[<xref ref-type="bibr" rid="pone.0158770.ref012">12</xref>]. The logarithm of the HR (logHR) was assumed to have a normal distribution. If CIs were reported, SEs for the logHRs were calculated. Engauge Digitizer (4.1) was used to read the Kaplan-Meier curves and extract data for reconstruction if the survival data were only provided in the form of figures. The data extraction was independently performed by two investigators, and any discrepancies were resolved by group discussion and consensus.</p>
</sec>
<sec id="sec005">
<title>Statistical analysis</title>
<p>Standard meta-analysis methods[<xref ref-type="bibr" rid="pone.0158770.ref013">13</xref>] were applied to evaluate the overall effect of the NLR on the prognosis of PCa patients. Because the statistical methods (log-rank and Cox model) used in the eligible studies were inconsistent, the results were combined using the generic inverse variance method[<xref ref-type="bibr" rid="pone.0158770.ref013">13</xref>]. The consistency of the results (effect sizes) among studies was investigated using two heterogeneity tests: Cochran’s Q test and Higgins’s I-squared test. If heterogeneity was observed (Q test P value &lt;0.10 and I<sup>2</sup>&gt;50%), a meta-analysis was performed by applying the random-effects model[<xref ref-type="bibr" rid="pone.0158770.ref014">14</xref>]; otherwise, the fixed-effects model was applied.</p>
<p>Sensitivity to influential studies was evaluated by recalculating the pooled HRs after omitting each study from the meta-analysis consecutively (leave-one-out procedure). Subgroup analysis of the more homogeneous set of studies (i.e., those using the same stratification and study design features) was adopted as an additional sensitivity test.</p>
<p>Publication bias (i.e., negative trials are cited less frequently and therefore are more likely to be missed in the search for relevant studies) of the studies was analyzed using Begg’s funnel plot and Egger’s linear regression test. The “trim and fill” method was used to evaluate the influence of the missing publication on the overall effect[<xref ref-type="bibr" rid="pone.0158770.ref015">15</xref>]. Unless otherwise noted, no significant heterogeneity or publication bias was detected among the included studies. All statistical analyses were conducted with STATA version 12.0 software (STATA Corporation, College Station, TX, USA) and Revman version 5.3 software (Review Manager (RevMan) [Computer program]. Version [5.3]. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014). All statistical tests were two-sided, and the significance level was set at 5%.</p>
</sec>
</sec>
<sec id="sec006" sec-type="results">
<title>Results</title>
<sec id="sec007">
<title>Literature searches and study characteristics</title>
<p>The selection flow of the relevant articles is shown in <xref ref-type="fig" rid="pone.0158770.g001">Fig 1</xref>. The initial search algorithm retrieved 131 studies. After removal of duplicates, two investigators independently screened the titles and abstracts of the remaining studies according to the predetermined criteria. Thirty-six studies remained after excluding case reports, reviews, editorials and irrelevant studies. After the full texts and bibliographies were screened, another 14 studies were removed owing to the inclusion of insufficient survival data for the meta-analysis. Thus, 22 relevant studies[<xref ref-type="bibr" rid="pone.0158770.ref016">16</xref>–<xref ref-type="bibr" rid="pone.0158770.ref037">37</xref>] published from 2012 to 2015 were included in the meta-analysis. The characteristics of the included studies are summarized in <xref ref-type="supplementary-material" rid="pone.0158770.s006">S1 Table</xref>.</p>
<fig id="pone.0158770.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0158770.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Flow chart outlining the study selection process.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0158770.g001" xlink:type="simple"/>
</fig>
<p>In the 22 selected studies concerning the association between the NLR and PCa prognosis, 16 cohorts informed the link between the NLR and OS, seven studies investigated the NLR and RFS, six cohorts reported a link between the NLR and PFS, six cohorts provided correlations between the NLR and PSARS, five studies reported an association between the NLR and BCR (<xref ref-type="supplementary-material" rid="pone.0158770.s006">S1 Table</xref>). A meta-analysis was employed for each end point.</p>
</sec>
<sec id="sec008">
<title>NLR and PSARS in mCRPC</title>
<p>Our meta-analysis detected a significant correlation between the NLR and PSARS. The pooled estimate from 6 cohorts indicated that patients with elevated pre-treatment NLRs tended to have 1.69-fold lower PSARSs after docetaxel- or cabazitaxel-based chemotherapy and androgen synthesis inhibitor (ASI) treatment (abiraterone or ketoconazole) compared to those patients with NLR below cut-off values(OR = 1.69, 95% CI: 1.40–1.98) (<xref ref-type="table" rid="pone.0158770.t001">Table 1</xref>).</p>
<table-wrap id="pone.0158770.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0158770.t001</object-id>
<label>Table 1</label> <caption><title>Meta-analysis of NLRs based on different end points.</title></caption>
<alternatives>
<graphic id="pone.0158770.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0158770.t001" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="justify">End Points</th>
<th align="justify">Cohorts</th>
<th align="justify">Patients</th>
<th align="justify">HR/OR (95% CI)</th>
<th align="justify">Heterogeneity<xref ref-type="table-fn" rid="t001fn001"><sup>1</sup></xref></th>
<th align="justify">Effects Model</th>
</tr>
</thead>
<tbody>
<tr>
<td align="justify"><bold>OS</bold></td>
<td align="justify">16</td>
<td align="justify">15298</td>
<td align="justify">HR = 1.40(1.25–1.55)</td>
<td align="justify">I<sup>2</sup> = 60.0%, P = 0.001</td>
<td align="justify">Random</td>
</tr>
<tr>
<td align="justify"><bold>PFS</bold></td>
<td align="justify">6</td>
<td align="justify">1629</td>
<td align="justify">HR = 1.42(1.23–1.61)</td>
<td align="justify">I<sup>2</sup> = 2.4%, P = 0.401</td>
<td align="justify">Fixed</td>
</tr>
<tr>
<td align="justify"><bold>BCR</bold></td>
<td align="justify">4</td>
<td align="justify">10171</td>
<td align="justify">HR = 1.12(1.02–1.21)</td>
<td align="justify">I<sup>2</sup> = 11.7%, P = 0.339</td>
<td align="justify">Fixed</td>
</tr>
<tr>
<td align="justify"><bold>PSARS</bold></td>
<td align="justify">6</td>
<td align="justify">3194</td>
<td align="justify">OR = 1.69(1.40–1.98)</td>
<td align="justify">I<sup>2</sup> = 0.0%, P = 0.590</td>
<td align="justify">Fixed</td>
</tr>
<tr>
<td align="justify"><bold>RFS</bold></td>
<td align="justify">7</td>
<td align="justify">11745</td>
<td align="justify">HR = 1.38(1.01–1.75)</td>
<td align="justify">I<sup>2</sup> = 79.2%, P = 0.000</td>
<td align="justify">Random</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p><sup>1</sup>Heterogeneity was evaluated by Higgins I-squared test (I<sup>2</sup>) and Cochran’s Q test (p).</p></fn>
<fn id="t001fn002"><p>A p value of the Q test &gt;0.10 and I<sup>2</sup> &lt;50% indicate homogeneity.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>Subgroup analysis by therapy was conducted. The patients in the two cohorts received ASI, whereas chemotherapy agents such as docetaxel or cabazitaxel were administered in the remaining cohorts. The association of elevated pre-treatment NLRs with lower PSARS was replicated in the cohorts that received chemotherapy (OR = 1.68, 95% CI: 1.39–1.97). However, an elevated NLR was not significantly associated with PSARS in patients who received ASI (OR = 3.68, 95% CI: 0.37–6.99) (<xref ref-type="fig" rid="pone.0158770.g002">Fig 2A</xref>)</p>
<fig id="pone.0158770.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0158770.g002</object-id>
<label>Fig 2</label>
<caption>
<title/>
<p>Forest plot and meta-analysis of studies evaluating the association between an elevated NLR and PSARS (A), BCR (B), PFS (C), RFS (D), OS (E).</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0158770.g002" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec009">
<title>NLR and BCR in PCa after radical prostatectomy</title>
<p>Five studies investigated the association between an elevated NLR and BCR in PCa patients after radical prostatectomy. Two studies by Sharam V and Lee H revealed that patients with higher NLRs experienced BCR significantly sooner. The remaining two studies by Zhang G M and Young Suk identified a similar but not significant trend. However, a significant, albeit modest, effect was observed after integration into our meta-analysis, with a 1.12-fold higher BCR after radical prostatectomy in patients with an elevated preoperational NLR (HR = 1.12, 95% CI: 1.02–1.21) (<xref ref-type="fig" rid="pone.0158770.g002">Fig 2B</xref>) (<xref ref-type="table" rid="pone.0158770.t001">Table 1</xref>).</p>
</sec>
<sec id="sec010">
<title>NLR and OS in PCa</title>
<p>Fourteen studies reported a correlation between pre-treatment NLR and OS in PCa patients. Two independent cohorts were included in the studies of R.J. Van et al and Sonpavde G et al; we labeled these cohorts R.J Van/TAX327, R.J Van/VENICE, Sonpavde G 1, and Sonpavde 2. Thus, a total of 16 cohorts were included in the OS analysis.</p>
<p>For the overall population, a random (I–V) analysis was selected due to heterogeneity (I<sup>2</sup> = 60.0%, P = 0.001). The pooled HR of 1.40 (95% CI: 1.25–1.55) indicates that patients with elevated NLRs are expected to have shorter OS (<xref ref-type="fig" rid="pone.0158770.g002">Fig 2E</xref>) (<xref ref-type="table" rid="pone.0158770.t001">Table 1</xref>).</p>
<p>In the subgroup analysis based on ethnicity, an elevated NLR appeared to be a stronger predictor of risk in Asian patients than Caucasian patients, with HRs of 2.25 (95% CI: 1.08–3.41) and 1.39 (95% CI: 1.24–1.53), respectively (<xref ref-type="table" rid="pone.0158770.t002">Table 2</xref>). When the patients were stratified by status, an elevated NLR was significantly associated with OS in mCRPC and LPC patients, with HRs of 1.45 (95% CI: 1.32–1.59) and 1.12 (95% CI: 1.01–1.23), respectively (<xref ref-type="table" rid="pone.0158770.t002">Table 2</xref>). Further subgroup analysis based on cut-off value (NLR≥5: HR = 1.40, 95% CI: 1.15–1.66 VS. NLR&lt;5: HR = 1.41, 95% CI: 1.21–1.62) and sample size (n&gt;300: HR = 1.39, 95% CI: 1.23–1.56, vs. n&lt;300: HR = 1.43, 95% CI: 1.11–1.74) produced similar results (<xref ref-type="table" rid="pone.0158770.t002">Table 2</xref>).</p>
<table-wrap id="pone.0158770.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0158770.t002</object-id>
<label>Table 2</label> <caption><title>Subgroup meta-analysis of the NLR and OS.</title></caption>
<alternatives>
<graphic id="pone.0158770.t002g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0158770.t002" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center">Subgroup</th>
<th align="center">Factor</th>
<th align="center">Cohort numbers</th>
<th align="center">HR(95%CI)</th>
<th align="center">Heterogeneity</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" rowspan="2"><bold>Ethnicity</bold></td>
<td align="center">Caucasian</td>
<td align="center">13</td>
<td align="center">1.39(1.24–1.53)</td>
<td align="center">I<sup>2</sup> = 0.0%,P = 0.546</td>
</tr>
<tr>
<td align="center">Asian</td>
<td align="center">3</td>
<td align="center">2.25(1.08–3.41)</td>
<td align="center">I<sup>2</sup> = 64.3%,P = 0.001</td>
</tr>
<tr>
<td align="center" rowspan="2"><bold>Patient Status</bold></td>
<td align="center">mCRPC</td>
<td align="center">12</td>
<td align="center">1.45(1.32–1.59)</td>
<td align="center">I<sup>2</sup> = 16.2%,P = 0.286</td>
</tr>
<tr>
<td align="center">LPC</td>
<td align="center">3</td>
<td align="center">1.12(1.01–1.23)</td>
<td align="center">I<sup>2</sup> = 6.9%, P = 0.342</td>
</tr>
<tr>
<td align="center" rowspan="2"><bold>Sample Size</bold></td>
<td align="center">n&gt;300</td>
<td align="center">9</td>
<td align="center">1.39(1.23–1.56)</td>
<td align="center">I<sup>2</sup> = 73.5%,P = 0.000</td>
</tr>
<tr>
<td align="center">n&lt;300</td>
<td align="center">7</td>
<td align="center">1.43(1.11–1.74)</td>
<td align="center">I<sup>2</sup> = 10.7%,P = 0.348</td>
</tr>
<tr>
<td align="center" rowspan="2"><bold>Cut-off value</bold></td>
<td align="center">NLR≥5</td>
<td align="center">7</td>
<td align="center">1.40(1.15–1.66)</td>
<td align="center">I<sup>2</sup> = 68.3%,P = 0.004</td>
</tr>
<tr>
<td align="center">NLR&lt;5</td>
<td align="center">9</td>
<td align="center">1.41(1.21–1.62)</td>
<td align="center">I<sup>2</sup> = 56.5%,P = 0.019</td>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
</sec>
<sec id="sec011">
<title>NLR and PFS in CRPC</title>
<p>Six cohorts exhibited an association between an elevated NLR and PFS in CRPC. The pooled-effect estimates (HR = 1.42, 95% CI: 1.23–1.61) indicated a significant correlation between an elevated pre-treatment NLR and worse PFS in CRPC (<xref ref-type="table" rid="pone.0158770.t001">Table 1</xref>) (<xref ref-type="fig" rid="pone.0158770.g002">Fig 2C</xref>).</p>
</sec>
<sec id="sec012">
<title>NLR and RFS in LPC after radical prostatectomy</title>
<p>Seven studies documented RFS data. Two of these studies reported that the NLR was a significant prognostic indicator, whereas the remaining studies did not observe a notable association between an elevated NLR and shorter RFS. However, our meta-analysis of these studies indicated a significant correlation between these factors, with a pooled HR of 1.38 (95% CI: 1.01–1.75, I<sup>2</sup> = 79.2%, p = 0.00) (<xref ref-type="table" rid="pone.0158770.t001">Table 1</xref>, <xref ref-type="fig" rid="pone.0158770.g002">Fig 2D</xref>) under the random-effects model.</p>
<sec id="sec013">
<title>Extensive statistical analysis</title>
<p>To verify the above results obtained using Stata, another analysis was conducted using generic inverse variance method via Revman 5.3. <xref ref-type="fig" rid="pone.0158770.g003">Fig 3</xref> showed similar results in PSARS, BCR, OS, RFS, and PFS analysis when generic inverse variance method was employed in Revman.</p>
<fig id="pone.0158770.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0158770.g003</object-id>
<label>Fig 3</label>
<caption>
<title/>
<p>Forest plot and meta-analysis of studies evaluating the association between an elevated NLR and PSARS (A), BCR (B), PFS (C), RFS (D), OS (E).</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0158770.g003" xlink:type="simple"/>
</fig>
</sec>
</sec>
<sec id="sec014">
<title>Publication bias and heterogeneity evaluation</title>
<p>Begg’s funnel plot and Egger’s test were employed to assess the overt publication bias in each meta-analysis in this study. Publication biases were identified in the OS analysis by Egger’s test (p&gt;|t| = 0.002) and in the PSARS analysis with Pr&gt;|Z| = 0.024 by Begg’s funnel plot and p&gt;|t| = 0.013 by Egger’s test. We applied “trim and fill” analysis to identify the source of the publication bias. It was estimated that there were five unpublished studies evaluating the role of the NLR in OS (<xref ref-type="supplementary-material" rid="pone.0158770.s001">S1A Fig</xref>) and three unpublished studies evaluating the role of NLR in PSARS (<xref ref-type="supplementary-material" rid="pone.0158770.s001">S1B Fig</xref>). The results of the filled meta-analysis that combined estimated unpublished studies correlated well with our primary pooled results with a pooled HR = 1.40 (95% CI: 1.25–1.57) for the NLR and OS and a pooled OR = 1.71 (95% CI: 1.46–2.01) for the NLR and PSARS. No obvious publication biases were detected in the other analyses.</p>
<p>Sensitivity analysis indicated that the majority of the heterogeneity in the OS analysis was contributed by the studies by Bahig H et al. and Sharma et al. (<xref ref-type="supplementary-material" rid="pone.0158770.s002">S2A Fig</xref>). The main source of heterogeneity in these two studies was the presentation of data from univariate analysis. After excluding these studies, the corresponding pooled HR of 1.46 (95% CI: 1.36–1.56) was not significantly altered and exhibited no obvious heterogeneity (I<sup>2</sup> = 13.1%, p = 0.31), indicating the reliability of the results. Subgroup analysis performed as an additional sensitivity test also indicated the source of heterogeneity. Statistical methods (univariate analysis) were also the major contributor of heterogeneity in the RFS analysis (<xref ref-type="supplementary-material" rid="pone.0158770.s002">S2B Fig</xref>).</p>
</sec>
</sec>
<sec id="sec015" sec-type="conclusions">
<title>Discussion</title>
<p>In the present study, we utilized 18,092 cases from 22 related studies to evaluate the prognostic role of the NLR in PCa. To the best of our knowledge, this is the first meta-analysis to investigate the relationship between an elevated NLR and PSARS, BCR. The results indicated that an elevated NLR was a mild risk factor for BCR in PCa patients after radical prostatectomy. Furthermore, we determined that an elevated NLR was a strong predictor of PSARS in mCRPC patients. An elevated NLR predicted worse OS, PFS, and RFS, in contrast to the results of a previous meta-analysis by Yin et al. These authors found that an elevated NLR was significantly associated with OS in mCRPC but not LPC. However, our analysis included more studies and thus more available evidence with less heterogeneity, and we demonstrated that an elevated NLR was significantly associated with OS not only in mCRPC but also in LPC. By contrast, a lower risk was observed in localized LPC.</p>
<p>A significant association between an elevated NLR and RFS in LPC was identified that was not reported in the previous study. The prognostic value of the NLR has been demonstrated in many malignancies[<xref ref-type="bibr" rid="pone.0158770.ref038">38</xref>–<xref ref-type="bibr" rid="pone.0158770.ref040">40</xref>]. An elevated NLR may be associated with both an increased neutrophil-dependent systemic inflammatory response and a lower lymphocyte-mediated antitumor immune response, reflecting a supportive tumor microenvironment[<xref ref-type="bibr" rid="pone.0158770.ref041">41</xref>,<xref ref-type="bibr" rid="pone.0158770.ref042">42</xref>]. Neutrophils are the predominant leukocyte subset in human peripheral blood and play an important role in tumor development by producing cytokines, proteases, and reactive oxygen species (ROS) and interacting with other immune cells[<xref ref-type="bibr" rid="pone.0158770.ref009">9</xref>]. Tumor-associated neutrophils can favor genetic instability via the release of ROS, promote tumor cell proliferation via elastase, sustain angiogenesis via the release of vascular endothelial growth factor (VEGF), enhance neoplastic cell invasiveness by secreting hepatocyte growth factor (HGF), oncostatin M (OSM)[<xref ref-type="bibr" rid="pone.0158770.ref043">43</xref>], and matrix metallopeptidase 9 (MMP-9), and suppress effective antitumor CD8<sup>+</sup> T cell immunity via arginase expression[<xref ref-type="bibr" rid="pone.0158770.ref044">44</xref>]. By contrast, lymphocytes are critical components of antitumor immunity. CD8<sup>+</sup> T lymphocytes, which recognize endogenous intracellular antigens presented by MHC class I molecules, are directly capable of killing tumor cells[<xref ref-type="bibr" rid="pone.0158770.ref045">45</xref>]. CD4<sup>+</sup> T lymphocytes are central to immune system functions and play a vital role in tumor immunity. CD4<sup>+</sup> T lymphocytes (also known as helper T lymphocytes) recognize antigens presented by MHC class II molecules, assist cytotoxic CD8<sup>+</sup> T cells, and aid antibody production by B lymphocytes, thereby increasing the efficiency of tumor destruction[<xref ref-type="bibr" rid="pone.0158770.ref046">46</xref>]. Moreover, CD4<sup>+</sup> T cells can directly or indirectly lyse tumor cells[<xref ref-type="bibr" rid="pone.0158770.ref046">46</xref>]. In addition to their antibody production capacity, B lymphocytes are involved in tumor surveillance by boosting T lymphocyte responses, serving as local antigen-presenting cells, and forming tertiary lymphoid structures in mutual cooperation with T cells and dendritic cells[<xref ref-type="bibr" rid="pone.0158770.ref047">47</xref>].</p>
<p>Recently, emerging studies have identified a heterogeneous population of myeloid-derived suppressor cells (MDSCs) that suppress tumour immunity responses and consequently significantly impede anti-cancer therapies. MDSCs are not a defined subset of myeloid cells, but rather a heterogeneous population of myeloid progenitor cells and immature myeloid cells[<xref ref-type="bibr" rid="pone.0158770.ref048">48</xref>]. In pathological conditions, such as cancer, MDSCs are expanded and activated by various factors produced by tumour cells and/or by stromal cells in the tumour microenvironment[<xref ref-type="bibr" rid="pone.0158770.ref048">48</xref>]. C. M. Diaz-Montero et al found that the percent and absolute number of MDSCs are significantly increased in the peripheral blood of patients with a range of solid tumours, including prostate cancer, than healthy volunteers[<xref ref-type="bibr" rid="pone.0158770.ref049">49</xref>]. More recently, two studies demonstrated that the CSF1R[<xref ref-type="bibr" rid="pone.0158770.ref050">50</xref>] and IL-6[<xref ref-type="bibr" rid="pone.0158770.ref051">51</xref>] pathways play critical roles in the migration of MDSCs to tumours microenvironments. MDSCs suppress tumour immunity mainly through its remarkable ability to suppress T-cell responses. Extensive studies have detailed how MDSCs mediated suppression of T-cell function through the release of enzymes (arginase 1 and iNOS), reactive oxygen species and peroxynitrite[<xref ref-type="bibr" rid="pone.0158770.ref048">48</xref>]. Furthermore, MDSCs also indirectly mediate T cell function by inducing T regulatory cells[<xref ref-type="bibr" rid="pone.0158770.ref048">48</xref>]. In addition to suppressing T cells, MDSCs also perturb tumour immunity in regulating macrophages and nature kill cells[<xref ref-type="bibr" rid="pone.0158770.ref052">52</xref>].</p>
<p>Hypothetically, the combined index of the elevated NLR likely reflects a favorable immune microenvironment for tumor development and metastasis. However, the exact mechanisms underlying the elevation in the NLR and the unfavorable outcomes are unknown. First, some T lymphocyte subsets have both pro- and antitumor properties. For example, CD4<sup>+</sup> T lymphocytes can be further divided into TH<sub>1</sub> cells, TH<sub>2</sub> cells, TH<sub>17</sub> cells and regulatory T cells. TH<sub>17</sub> cells and regulatory T cells promote tumor progression. Because the NLR is a relative parameter, whether the increase in the NLR is due to a relative increase in neutrophils or decrease in lymphocytes in unclear. Importantly, changes in the lymphocyte subsets were not defined. Consequently, the NLR is an approximate index with heterogeneity that reflects the immune microenvironment for tumor development, which may explain the inconsistent results of the included studies. More specific NLR (e.g., NL<sub>CD4TH2</sub>R, NL<sub>CD4TH17</sub>R, and NL<sub>B</sub>R) indices should be explored to generate more precise predictions in future studies. Second, tumors are often infiltrated by various numbers of immune cells, which are also involved in cancer progression. However, the process of circulating immune cell recruitment to the tumor is not clear. Whether intra-tumor neutrophils are recruited from the bone marrow/blood pool of neutrophils or the spleen is unknown[<xref ref-type="bibr" rid="pone.0158770.ref053">53</xref>]. Moreover, neutrophils may influence the recruitment and differentiation of macrophages by releasing various cytokines[<xref ref-type="bibr" rid="pone.0158770.ref053">53</xref>].</p>
<p>Immune cells infiltrating prostate cancer tissues may be influenced by the tumor environment to facilitate PCa progression, which adds another level of complexity to the mechanisms of these cells in cancer development. Abundant immune cells have been detected in prostate tumor tissues by immunohistochemistry using different markers (CD3<sup>+</sup>, CD8<sup>+</sup>, CD20<sup>+</sup>, CD56<sup>+</sup>, CD68<sup>+</sup> and Foxp3<sup>+</sup>)[<xref ref-type="bibr" rid="pone.0158770.ref054">54</xref>]. One study demonstrated that patients with very low and very high CD3<sup>+</sup> T cell numbers had shorter BCR survival than patients with intermediate numbers of T cells; however, no significant association was identified when CD20 was used to mark B lymphocytes in the same patients[<xref ref-type="bibr" rid="pone.0158770.ref055">55</xref>]. Nora Ness et al. reported that the infiltration of high densities of CD8<sup>+</sup> lymphocytes into prostate tumor epithelial areas was an independent risk factor for BCR [<xref ref-type="bibr" rid="pone.0158770.ref056">56</xref>]. Kiniwa et al. determined that regulatory T cells (CD8<sup>+</sup> Foxp3<sup>+</sup> or CD4<sup>+</sup>CD25<sup>+</sup>) present in prostate tumors mediate immunosuppression by suppressing naive T cell proliferation[<xref ref-type="bibr" rid="pone.0158770.ref057">57</xref>]. Furthermore, Vincenzo et al. revealed that cytotoxic T lymphocytes that infiltrated in the prostate tumor were immunosuppressed by substances secreted in the tumor microenvironment[<xref ref-type="bibr" rid="pone.0158770.ref058">58</xref>].</p>
<p>The potential of NLR to predict PSARS in response to drug treatments in mCRPC patients has been studied extensively, but less is known about the mechanisms. In our meta-analysis, a high NLR was associated with a low PSARS to chemotherapy but not ASI, thus suggesting that mCRPC patients with an elevated NLR may receive greater benefit from chemotherapy than ASI. Here, we hypothesize that different tumor immune environments after treatment with chemotherapy or ASI may be a contributing factor and subsequently affect the effectiveness of the treatments. Supporting this hypothesis, an increase in the relative densities of CD3<sup>+</sup> and CD8<sup>+</sup> T lymphocytes as well as CD68<sup>+</sup> macrophages was observed under androgen depletion treatment compared to radical prostatectomy[<xref ref-type="bibr" rid="pone.0158770.ref054">54</xref>]. Additionally, NLR has been positively associated with PSA in men without prostatic disease[<xref ref-type="bibr" rid="pone.0158770.ref030">30</xref>] as well as with PCa[<xref ref-type="bibr" rid="pone.0158770.ref059">59</xref>]. McDonald et al. proposed that the NLR reflects the balance between innate (neutrophils) and adaptive (lymphocytes) immune responses; therefore, its association with higher serum PSA levels may indicate impairment in the adaptive host’s ability to control inflammation[<xref ref-type="bibr" rid="pone.0158770.ref030">30</xref>]. This finding may indicate that ASIs are more dependent on adaptive immune cells to fulfil their therapeutic effectiveness compared to chemotherapy.</p>
<p>Future studies should investigate the functions of specific subsets of neutrophils and lymphocytes due to the complex roles of immune cells in cancer development. This approach may facilitate the identification of new anticancer therapies or improve the effectiveness of existing treatments. The relationship between circulating immune cells and tumor-infiltrating immune cells is another vital problem. The mechanisms by which immune cells are recruited into tumor tissues to promote tumor progression should also be considered as therapeutic targets. The mechanisms underlying an elevated NLR and the response to anticancer treatment should also be explored. Such studies would facilitate the selection of patients who are more lost likely to benefit from drugs developed for mCRPC.</p>
<p>Our study has several limitations that should be carefully considered. First, studies lacking sufficient survival data for the meta-analysis were excluded. Second, the number of relevant studies was not sufficient to obtain a robust conclusion in some endpoint analyses. Another limitation of this study is the variety of NLR cut-off values employed in related studies. Further prospective studies are needed to confirm these conclusions.</p>
</sec>
<sec id="sec016" sec-type="conclusions">
<title>Conclusion</title>
<p>In conclusion, this meta-analysis provides evidence that an elevated NLR predicts lower PSARS after chemotherapy and poor survival outcomes in PCa. These two inexpensive and easily accessible indicators can help stratify high-risk patients and guide therapy choices. Future studies should seek to identify more specific NLRs for consistent and precise predictions. A greater understanding of the mechanisms underlying the role of the NLR in PCa progression will facilitate the development of new anticancer strategies.</p>
</sec>
<sec id="sec017">
<title>Supporting Information</title>
<supplementary-material id="pone.0158770.s001" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pone.0158770.s001" xlink:type="simple">
<label>S1 Fig</label>
<caption>
<title>Funnel plot adjusted with trim and fill method.</title>
<p>A: Trim and Fill analysis of NLR and OS; B: Trim and Fill analysis of NLR and PSARS. Circles: included studies. Diamonds: presumed missing studies.</p>
<p>(TIF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0158770.s002" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pone.0158770.s002" xlink:type="simple">
<label>S2 Fig</label>
<caption>
<title>Heterogeneity resource evaluation.</title>
<p>A: Sensitive analysis of NLR and OS; B: Sensitive analysis of NLR and RFS.</p>
<p>(TIF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0158770.s003" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pone.0158770.s003" xlink:type="simple">
<label>S1 File</label>
<caption>
<title>PRISMA 2009 checklist.</title>
<p>(DOC)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0158770.s004" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pone.0158770.s004" xlink:type="simple">
<label>S2 File</label>
<caption>
<title>Cover letter from Nature Publication Group language edition team for the first edition of this manuscript.</title>
<p>(PDF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0158770.s005" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pone.0158770.s005" xlink:type="simple">
<label>S3 File</label>
<caption>
<title>Marked-up copy after edited by Nature Publication Group language edition team.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0158770.s006" mimetype="application/vnd.ms-excel" position="float" xlink:href="info:doi/10.1371/journal.pone.0158770.s006" xlink:type="simple">
<label>S1 Table</label>
<caption>
<title>Characteristics of all studies.</title>
<p>(XLS)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<p>We acknowledge all patients included in this study.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pone.0158770.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Torre</surname> <given-names>LA</given-names></name>, <name name-style="western"><surname>Bray</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Siegel</surname> <given-names>RL</given-names></name>, <name name-style="western"><surname>Ferlay</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Lortet-tieulent</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Jemal</surname> <given-names>A</given-names></name>. <article-title>Global Cancer Statistics, 2012</article-title>. <source>CA a cancer J Clin</source>. <year>2015</year>;<volume>65</volume>: <fpage>87</fpage>–<lpage>108</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3322/caac.21262" xlink:type="simple">10.3322/caac.21262</ext-link></comment></mixed-citation></ref>
<ref id="pone.0158770.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Collin</surname> <given-names>SM</given-names></name>, <name name-style="western"><surname>Martin</surname> <given-names>RM</given-names></name>, <name name-style="western"><surname>Metcalfe</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Gunnell</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Albertsen</surname> <given-names>PC</given-names></name>, <name name-style="western"><surname>Neal</surname> <given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Prostate-cancer mortality in the USA and UK in 1975–2004: an ecological study</article-title>. <source>Lancet Oncol</source>. <year>2008</year>;<volume>9</volume>: <fpage>445</fpage>–<lpage>452</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S1470-2045(08)70104-9" xlink:type="simple">10.1016/S1470-2045(08)70104-9</ext-link></comment> <object-id pub-id-type="pmid">18424233</object-id></mixed-citation></ref>
<ref id="pone.0158770.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ferlay</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Soerjomataram</surname> <given-names>II</given-names></name>, <name name-style="western"><surname>Dikshit</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Eser</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Mathers</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Rebelo</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012</article-title>. <source>Int J Cancer</source>. <year>2014</year>;<volume>136</volume>: <fpage>E359</fpage>–<lpage>86</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/ijc.29210" xlink:type="simple">10.1002/ijc.29210</ext-link></comment> <object-id pub-id-type="pmid">25220842</object-id></mixed-citation></ref>
<ref id="pone.0158770.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Potosky</surname> <given-names>AL</given-names></name>, <name name-style="western"><surname>Kessler</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Gridley</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Brown</surname> <given-names>CC</given-names></name>, <name name-style="western"><surname>Horm</surname> <given-names>JW</given-names></name>. <article-title>Rise in prostatic cancer incidence associated with increased use of transurethral resection</article-title>. <source>JNatlCancer Inst</source>. <year>1990</year>;<volume>82</volume>: <fpage>1624</fpage>–<lpage>1628</lpage>.</mixed-citation></ref>
<ref id="pone.0158770.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Potosky</surname> <given-names>AL</given-names></name>, <name name-style="western"><surname>Miller</surname> <given-names>BA</given-names></name>, <name name-style="western"><surname>Albertsen</surname> <given-names>PC</given-names></name>, <name name-style="western"><surname>Kramer</surname> <given-names>BS</given-names></name>. <article-title>The role of increasing detection in the rising incidence of prostate cancer</article-title>. <source>JAMA</source>. <year>1995</year>;<volume>273</volume>: <fpage>548</fpage>–<lpage>552</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1001/jama.273.7.548" xlink:type="simple">10.1001/jama.273.7.548</ext-link></comment> <object-id pub-id-type="pmid">7530782</object-id></mixed-citation></ref>
<ref id="pone.0158770.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Li</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Djenaba</surname> <given-names>JA</given-names></name>, <name name-style="western"><surname>Soman</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Rim</surname> <given-names>SH</given-names></name>, <name name-style="western"><surname>Master</surname> <given-names>VA</given-names></name>. <article-title>Recent trends in prostate cancer incidence by age, cancer stage, and grade, the United States, 2001–2007</article-title>. <source>Prostate Cancer</source>. <year>2012</year>;<volume>2012</volume>: <fpage>691380</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1155/2012/691380" xlink:type="simple">10.1155/2012/691380</ext-link></comment> <object-id pub-id-type="pmid">23251806</object-id></mixed-citation></ref>
<ref id="pone.0158770.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Heidenreich</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Bolla</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Joniau</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Mason</surname> <given-names>MD</given-names></name>, <name name-style="western"><surname>Matveev</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Mottet</surname> <given-names>N</given-names></name>, <etal>et al</etal>. <source>Guidelines on Prostate Cancer. Update</source>. <year>2011</year>;<volume>53</volume>: <fpage>31</fpage>–<lpage>45</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.eururo.2007.09.002" xlink:type="simple">10.1016/j.eururo.2007.09.002</ext-link></comment></mixed-citation></ref>
<ref id="pone.0158770.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pezaro</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Woo</surname> <given-names>HH</given-names></name>, <name name-style="western"><surname>Davis</surname> <given-names>ID</given-names></name>. <article-title>Prostate cancer: Measuring PSA</article-title>. <source>Intern Med J</source>. <year>2014</year>;<volume>44</volume>: <fpage>433</fpage>–<lpage>440</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/imj.12407" xlink:type="simple">10.1111/imj.12407</ext-link></comment> <object-id pub-id-type="pmid">24816306</object-id></mixed-citation></ref>
<ref id="pone.0158770.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Grivennikov</surname> <given-names>SI</given-names></name>, <name name-style="western"><surname>Greten</surname> <given-names>FR</given-names></name>, <name name-style="western"><surname>Karin</surname> <given-names>M</given-names></name>. <article-title>Immunity, Inflammation, and Cancer</article-title>. <source>Cell</source>. Elsevier Inc.; <year>2010</year>;<volume>140</volume>: <fpage>883</fpage>–<lpage>899</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cell.2010.01.025" xlink:type="simple">10.1016/j.cell.2010.01.025</ext-link></comment> <object-id pub-id-type="pmid">20303878</object-id></mixed-citation></ref>
<ref id="pone.0158770.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yin</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Xiao</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Qi</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Yin</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Gao</surname> <given-names>J</given-names></name>. <article-title>Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Prostate Cancer</article-title>. <source>Medicine (Baltimore)</source>. <year>2016</year>;<volume>95</volume>: <fpage>e2544</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/MD.0000000000002544" xlink:type="simple">10.1097/MD.0000000000002544</ext-link></comment></mixed-citation></ref>
<ref id="pone.0158770.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Stroup</surname> <given-names>DF</given-names></name>, <name name-style="western"><surname>Berlin</surname> <given-names>JA</given-names></name>, <name name-style="western"><surname>Morton</surname> <given-names>SC</given-names></name>, <name name-style="western"><surname>Olkin</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Williamson</surname> <given-names>GD</given-names></name>, <name name-style="western"><surname>Rennie</surname> <given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Meta-analysis of Observational Studies</article-title>. <year>2008</year>;<volume>283</volume>.</mixed-citation></ref>
<ref id="pone.0158770.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tierney</surname> <given-names>JF</given-names></name>, <name name-style="western"><surname>Stewart</surname> <given-names>LA</given-names></name>, <name name-style="western"><surname>Ghersi</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Burdett</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Sydes</surname> <given-names>MR</given-names></name>. <article-title>Practical methods for incorporating summary time-to-event data into meta-analysis</article-title>. <source>Trials</source>. <year>2007</year>;<volume>8</volume>: <fpage>16</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1745-6215-8-16" xlink:type="simple">10.1186/1745-6215-8-16</ext-link></comment> <object-id pub-id-type="pmid">17555582</object-id></mixed-citation></ref>
<ref id="pone.0158770.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sutton</surname> <given-names>AJ</given-names></name>, <name name-style="western"><surname>Abrams</surname> <given-names>KR</given-names></name>, <name name-style="western"><surname>Jones</surname> <given-names>DR</given-names></name>, <name name-style="western"><surname>Sheldon</surname> <given-names>T a</given-names></name>, <name name-style="western"><surname>Song</surname> <given-names>F</given-names></name>. <source>Methods for Meta-analysis in Medical Research</source>. <year>2000</year>; <volume>309</volume>.</mixed-citation></ref>
<ref id="pone.0158770.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>DerSimonian</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Laird</surname> <given-names>N</given-names></name>. <article-title>Meta-analysis in clinical trials</article-title>. <source>Control Clin Trials</source>. <year>1986</year>;<volume>7</volume>: <fpage>177</fpage>–<lpage>188</lpage>. 0197-2456(86)90046-2 [pii] <object-id pub-id-type="pmid">3802833</object-id></mixed-citation></ref>
<ref id="pone.0158770.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Duval</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Tweedie</surname> <given-names>R</given-names></name>. <article-title>Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis</article-title>. <source>Biometrics</source>. <year>2000</year>;<volume>56</volume>: <fpage>455</fpage>–<lpage>463</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.0006-341x.2000.00455.x" xlink:type="simple">10.1111/j.0006-341x.2000.00455.x</ext-link></comment> <object-id pub-id-type="pmid">10877304</object-id></mixed-citation></ref>
<ref id="pone.0158770.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lorente</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Mateo</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Templeton</surname> <given-names>AJ</given-names></name>, <name name-style="western"><surname>Zafeiriou</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Bianchini</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Ferraldeschi</surname> <given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use</article-title>. <source>Ann Oncol</source>. <year>2015</year>;<volume>26</volume>: <fpage>750</fpage>–<lpage>755</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/annonc/mdu587" xlink:type="simple">10.1093/annonc/mdu587</ext-link></comment> <object-id pub-id-type="pmid">25538172</object-id></mixed-citation></ref>
<ref id="pone.0158770.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kwon</surname> <given-names>YS</given-names></name>, <name name-style="western"><surname>Han</surname> <given-names>CS</given-names></name>, <name name-style="western"><surname>Yu</surname> <given-names>JW</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Modi</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Davis</surname> <given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Neutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate Cancer</article-title>. <source>Clin Genitourin Cancer</source>. Elsevier Inc.; <year>2015</year>; <fpage>1</fpage>–<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.clgc.2015.07.018" xlink:type="simple">10.1016/j.clgc.2015.07.018</ext-link></comment></mixed-citation></ref>
<ref id="pone.0158770.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chung</surname> <given-names>CH</given-names></name>. <article-title>Managing Premedications and the Risk for Reactions to Infusional Monoclonal Antibody Therapy</article-title>. <source>Oncologist</source>. <year>2008</year>;<volume>13</volume>: <fpage>725</fpage>–<lpage>732</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1634/theoncologist.2008-0012" xlink:type="simple">10.1634/theoncologist.2008-0012</ext-link></comment> <object-id pub-id-type="pmid">18586928</object-id></mixed-citation></ref>
<ref id="pone.0158770.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhanhg</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>HT</given-names></name>, <name name-style="western"><surname>Yang</surname> <given-names>Q</given-names></name>, <name name-style="western"><surname>Du</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Jia</surname> <given-names>WY</given-names></name>. <article-title>castration-resistant prostate cancer treated with docetaxel-based chemotherapy</article-title>. <source>TUMOUR</source>. <year>2015</year>;<volume>35</volume>: <fpage>333</fpage>–<lpage>339</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3781/j.issn.1000-7431.2015.33.707" xlink:type="simple">10.3781/j.issn.1000-7431.2015.33.707</ext-link></comment></mixed-citation></ref>
<ref id="pone.0158770.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nuhn</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Vaghasia</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Goyal</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Zhou</surname> <given-names>XC</given-names></name>, <name name-style="western"><surname>Carducci</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Eisenberger</surname> <given-names>MA</given-names></name>, <etal>et al</etal>. <article-title>Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel</article-title>. <source>BJU Int</source>. <year>2014</year>;<volume>114</volume>: <fpage>E11</fpage>–<lpage>E17</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/bju.12531" xlink:type="simple">10.1111/bju.12531</ext-link></comment> <object-id pub-id-type="pmid">24529213</object-id></mixed-citation></ref>
<ref id="pone.0158770.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhang</surname> <given-names>G-M</given-names></name>, <name name-style="western"><surname>Zhu</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Ma</surname> <given-names>X-C</given-names></name>, <name name-style="western"><surname>Qin</surname> <given-names>X-J</given-names></name>, <name name-style="western"><surname>Wan</surname> <given-names>F-N</given-names></name>, <name name-style="western"><surname>Dai</surname> <given-names>B</given-names></name>, <etal>et al</etal>. <article-title>Pretreatment Neutrophil-to-Lymphocyte Ratio</article-title>. <source>Medicine (Baltimore)</source>. <year>2015</year>;<volume>94</volume>: <fpage>e1473</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/MD.0000000000001473" xlink:type="simple">10.1097/MD.0000000000001473</ext-link></comment></mixed-citation></ref>
<ref id="pone.0158770.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yao</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Sejima</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Iwamoto</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Masago</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Morizane</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Honda</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>High neutrophil-to-lymphocyte ratio predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy</article-title>. <source>Int J Urol</source>. <year>2015</year>;<volume>22</volume>: <fpage>827</fpage>–<lpage>833</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/iju.12839" xlink:type="simple">10.1111/iju.12839</ext-link></comment> <object-id pub-id-type="pmid">26087772</object-id></mixed-citation></ref>
<ref id="pone.0158770.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sümbül</surname> <given-names>AT</given-names></name>, <name name-style="western"><surname>Sezer</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Abali</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Köse</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Gültepe</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Mertsoylu</surname> <given-names>H</given-names></name>, <etal>et al</etal>. <article-title>Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel</article-title>. <source>Int Urol Nephrol</source>. <year>2014</year>; <fpage>1</fpage>–<lpage>5</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s11255-014-0664-7" xlink:type="simple">10.1007/s11255-014-0664-7</ext-link></comment></mixed-citation></ref>
<ref id="pone.0158770.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>van Soest</surname> <given-names>RJ</given-names></name>, <name name-style="western"><surname>Templeton</surname> <given-names>AJ</given-names></name>, <name name-style="western"><surname>Vera-Badillo</surname> <given-names>FE</given-names></name>, <name name-style="western"><surname>Mercier</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Sonpavde</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Amir</surname> <given-names>E</given-names></name>, <etal>et al</etal>. <article-title>Neutrophil to lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials</article-title>. <source>Ann Oncol</source>. <year>2014</year>;<volume>2014</volume>: <fpage>743</fpage>–<lpage>749</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/annonc/mdu569" xlink:type="simple">10.1093/annonc/mdu569</ext-link></comment></mixed-citation></ref>
<ref id="pone.0158770.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shafique</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Proctor</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>McMillan</surname> <given-names>DC</given-names></name>, <name name-style="western"><surname>Qureshi</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Leung</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Morrison</surname> <given-names>DS</given-names></name>. <article-title>Systemic inflammation and survival of patients with prostate cancer: evidence from the Glasgow Inflammation Outcome Study</article-title>. <source>Prostate Cancer Prostatic Dis</source>. Nature Publishing Group; <year>2012</year>;<volume>15</volume>: <fpage>195</fpage>–<lpage>201</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/pcan.2011.60" xlink:type="simple">10.1038/pcan.2011.60</ext-link></comment> <object-id pub-id-type="pmid">22343838</object-id></mixed-citation></ref>
<ref id="pone.0158770.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Poyet</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Adank</surname> <given-names>J-P</given-names></name>, <name name-style="western"><surname>Keller</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Mortezavi</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Rabgang</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Pfister</surname> <given-names>B</given-names></name>, <etal>et al</etal>. <article-title>Mp66-05 Pretreatment Systemic Inflamatory Response Parameters Do Not Predict the Outcome in Men With Prostate Cancer Undergoing Radical Prostatectomy</article-title>. <source>J Urol</source>. <year>2015</year>;<volume>193</volume>: <fpage>e817</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.juro.2015.02.2358" xlink:type="simple">10.1016/j.juro.2015.02.2358</ext-link></comment></mixed-citation></ref>
<ref id="pone.0158770.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Leibowitz-Amit</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Templeton</surname> <given-names>AJ</given-names></name>, <name name-style="western"><surname>Omlin</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Pezaro</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Atenafu</surname> <given-names>EG</given-names></name>, <name name-style="western"><surname>Keizman</surname> <given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer</article-title>. <source>Ann Oncol</source>. <year>2014</year>;<volume>25</volume>: <fpage>657</fpage>–<lpage>62</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/annonc/mdt581" xlink:type="simple">10.1093/annonc/mdt581</ext-link></comment> <object-id pub-id-type="pmid">24458472</object-id></mixed-citation></ref>
<ref id="pone.0158770.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sonpavde</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Pond</surname> <given-names>GR</given-names></name>, <name name-style="western"><surname>Armstrong</surname> <given-names>AJ</given-names></name>, <name name-style="western"><surname>Clarke</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Vardy</surname> <given-names>JL</given-names></name>, <name name-style="western"><surname>Templeton</surname> <given-names>AJ</given-names></name>, <etal>et al</etal>. <article-title>Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Men With Metastatic Castration-Resistant Prostate Cancer</article-title>. <source>Clin Genitourin Cancer</source>. Elsevier Inc; <year>2014</year>;<volume>12</volume>: <fpage>317</fpage>–<lpage>324</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.clgc.2014.03.005" xlink:type="simple">10.1016/j.clgc.2014.03.005</ext-link></comment> <object-id pub-id-type="pmid">24806399</object-id></mixed-citation></ref>
<ref id="pone.0158770.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sharma</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Cockerill</surname> <given-names>PA</given-names></name>, <name name-style="western"><surname>Viers</surname> <given-names>BR</given-names></name>, <name name-style="western"><surname>Rangel</surname> <given-names>LJ</given-names></name>, <name name-style="western"><surname>Carlson</surname> <given-names>RE</given-names></name>, <name name-style="western"><surname>Karnes</surname> <given-names>RJ</given-names></name>, <etal>et al</etal>. <article-title>Mp6-05 the Association of Preoperative Neutrophil To Lymphocyte Ratio With Oncologic Outcomes Following Radical Prostatectomy for Prostate Cancer</article-title>. <source>J Urol</source>. Elsevier Ltd; <year>2015</year>;<volume>193</volume>: <fpage>e55</fpage>–<lpage>e56</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.juro.2015.02.252" xlink:type="simple">10.1016/j.juro.2015.02.252</ext-link></comment></mixed-citation></ref>
<ref id="pone.0158770.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>McDonald</surname> <given-names>AC</given-names></name>, <name name-style="western"><surname>Vira</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Vidal</surname> <given-names>AC</given-names></name>, <name name-style="western"><surname>Gan</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Freedland</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Taioli</surname> <given-names>E</given-names></name>. <article-title>Association between systemic inflammatory markers and serum prostate-specific antigen in men without prostatic disease—the 2001–2008 National Health and Nutrition Examination Survey</article-title>. <source>Prostate</source>. <year>2014</year>;<volume>74</volume>: <fpage>561</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/pros.22782" xlink:type="simple">10.1002/pros.22782</ext-link></comment> <object-id pub-id-type="pmid">24435840</object-id></mixed-citation></ref>
<ref id="pone.0158770.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Linton</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Pond</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Clarke</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Vardy</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Galsky</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Sonpavde</surname> <given-names>G</given-names></name>. <article-title>Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy</article-title>. <source>Clin Genitourin Cancer</source>. Elsevier Inc; <year>2013</year>;<volume>11</volume>: <fpage>423</fpage>–<lpage>430</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.clgc.2013.04.020" xlink:type="simple">10.1016/j.clgc.2013.04.020</ext-link></comment> <object-id pub-id-type="pmid">23816526</object-id></mixed-citation></ref>
<ref id="pone.0158770.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Proctor</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Morrison</surname> <given-names>DS</given-names></name>, <name name-style="western"><surname>Talwar</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Balmer</surname> <given-names>SM</given-names></name>, <name name-style="western"><surname>Fletcher</surname> <given-names>CD</given-names></name>, <name name-style="western"><surname>O’reilly</surname> <given-names>DSJ</given-names></name>, <etal>et al</etal>. <article-title>A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study</article-title>. <source>Eur J Cancer</source>. Elsevier Ltd; <year>2011</year>;<volume>47</volume>: <fpage>2633</fpage>–<lpage>2641</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ejca.2011.03.028" xlink:type="simple">10.1016/j.ejca.2011.03.028</ext-link></comment> <object-id pub-id-type="pmid">21724383</object-id></mixed-citation></ref>
<ref id="pone.0158770.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lee</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Jeong</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Hong</surname> <given-names>SK</given-names></name>, <name name-style="western"><surname>Byun</surname> <given-names>S-S</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>SE</given-names></name>, <name name-style="western"><surname>Oh</surname> <given-names>JJ</given-names></name>. <article-title>High preoperative neutrophil-lymphocyte ratio predicts biochemical recurrence in patients with localized prostate cancer after radical prostatectomy</article-title>. <source>World J Urol</source>. <year>2015</year>; <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00345-015-1701-6" xlink:type="simple">10.1007/s00345-015-1701-6</ext-link></comment></mixed-citation></ref>
<ref id="pone.0158770.ref034"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Templeton</surname> <given-names>AJ</given-names></name>, <name name-style="western"><surname>Pezaro</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Omlin</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>McNamara</surname> <given-names>MG</given-names></name>, <name name-style="western"><surname>Leibowitz-Amit</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Vera-Badillo</surname> <given-names>FE</given-names></name>, <etal>et al</etal>. <article-title>Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio</article-title>. <source>Cancer</source>. <year>2014</year>;<volume>120</volume>: <fpage>3346</fpage>–<lpage>3352</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/cncr.28890" xlink:type="simple">10.1002/cncr.28890</ext-link></comment> <object-id pub-id-type="pmid">24995769</object-id></mixed-citation></ref>
<ref id="pone.0158770.ref035"><label>35</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Minardi</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Scartozzi</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Montesi</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Santoni</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Burattini</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Bianconi</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Neutrophil-to-lymphocyte ratio may be associated with the outcome in patients with prostate cancer</article-title>. <source>Springerplus</source>. Springer International Publishing; <year>2015</year>;<volume>4</volume>: <fpage>255</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/s40064-015-1036-1" xlink:type="simple">10.1186/s40064-015-1036-1</ext-link></comment> <object-id pub-id-type="pmid">26085975</object-id></mixed-citation></ref>
<ref id="pone.0158770.ref036"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>McLachlan</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Chan</surname> <given-names>DL</given-names></name>, <name name-style="western"><surname>Crumbaker</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Marx</surname> <given-names>GM</given-names></name>. <article-title>Neutrophil–lymphocyte ratio prior to steroids as a prognostic marker in men with metastatic castration-resistant prostate cancer</article-title>. <source>Cancer Treat Commun</source>. Elsevier; <year>2015</year>;<volume>4</volume>: <fpage>81</fpage>–<lpage>85</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ctrc.2015.06.001" xlink:type="simple">10.1016/j.ctrc.2015.06.001</ext-link></comment></mixed-citation></ref>
<ref id="pone.0158770.ref037"><label>37</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bahig</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Taussky</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Delouya</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Nadiri</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Gagnon-Jacques</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Bodson-Clermont</surname> <given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Neutrophil count is associated with survival in localized prostate cancer. BMC Cancer</article-title>. <source>BMC Cancer</source>; <year>2015</year>;<volume>15</volume>: <fpage>594</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/s12885-015-1599-9" xlink:type="simple">10.1186/s12885-015-1599-9</ext-link></comment> <object-id pub-id-type="pmid">26292807</object-id></mixed-citation></ref>
<ref id="pone.0158770.ref038"><label>38</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wei</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Jiang</surname> <given-names>YZ</given-names></name>, <name name-style="western"><surname>Qian</surname> <given-names>WH</given-names></name>. <article-title>Prognostic role of NLR in urinary cancers: A meta-analysis</article-title>. <source>PLoS One</source>. <year>2014</year>;<volume>9</volume>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0092079" xlink:type="simple">10.1371/journal.pone.0092079</ext-link></comment></mixed-citation></ref>
<ref id="pone.0158770.ref039"><label>39</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Templeton</surname> <given-names>AJ</given-names></name>, <name name-style="western"><surname>McNamara</surname> <given-names>MG</given-names></name>, <name name-style="western"><surname>Šeruga</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Vera-Badillo</surname> <given-names>FE</given-names></name>, <name name-style="western"><surname>Aneja</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Ocaña</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: A systematic review and meta-analysis</article-title>. <source>Journal of the National Cancer Institute</source>. <year>2014</year>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/jnci/dju124" xlink:type="simple">10.1093/jnci/dju124</ext-link></comment></mixed-citation></ref>
<ref id="pone.0158770.ref040"><label>40</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Li</surname> <given-names>M-X</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>X-M</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>X-F</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>J-F</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>W-L</given-names></name>, <name name-style="western"><surname>Zhu</surname> <given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis</article-title>. <source>Int J Cancer</source>. <year>2014</year>;<volume>134</volume>: <fpage>2403</fpage>–<lpage>13</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/ijc.28536" xlink:type="simple">10.1002/ijc.28536</ext-link></comment> <object-id pub-id-type="pmid">24122750</object-id></mixed-citation></ref>
<ref id="pone.0158770.ref041"><label>41</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Coffelt</surname> <given-names>SB</given-names></name>, <name name-style="western"><surname>Kersten</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Doornebal</surname> <given-names>CW</given-names></name>, <name name-style="western"><surname>Weiden</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Vrijland</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Hau</surname> <given-names>C-S</given-names></name>, <etal>et al</etal>. <article-title>IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis</article-title>. <source>Nature</source>. <year>2015</year>;<volume>522</volume>: <fpage>345</fpage>–<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature14282" xlink:type="simple">10.1038/nature14282</ext-link></comment> <object-id pub-id-type="pmid">25822788</object-id></mixed-citation></ref>
<ref id="pone.0158770.ref042"><label>42</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Piccard</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Muschel</surname> <given-names>RJ</given-names></name>, <name name-style="western"><surname>Opdenakker</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Tazzyman</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Niaz</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Murdoch</surname> <given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Neutrophil-mediated tumour angiogenesis: Subversion of immune responses to promote tumour growth</article-title>. <source>Semin Cancer Biol</source>. <year>2013</year>;<volume>23</volume>: <fpage>149</fpage>–<lpage>158</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.critrevonc.2011.06.004" xlink:type="simple">10.1016/j.critrevonc.2011.06.004</ext-link></comment> <object-id pub-id-type="pmid">23410638</object-id></mixed-citation></ref>
<ref id="pone.0158770.ref043"><label>43</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Li</surname> <given-names>XF</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>DP</given-names></name>, <name name-style="western"><surname>Ouyang</surname> <given-names>FZ</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>MM</given-names></name>, <name name-style="western"><surname>Wu</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Kuang</surname> <given-names>DM</given-names></name>, <etal>et al</etal>. <article-title>Increased autophagy sustains the survival and pro-tumourigenic effects of neutrophils in human hepatocellular carcinoma</article-title>. <source>J Hepatol</source>. <year>2015</year>;<volume>62</volume>: <fpage>131</fpage>–<lpage>139</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jhep.2014.08.023" xlink:type="simple">10.1016/j.jhep.2014.08.023</ext-link></comment> <object-id pub-id-type="pmid">25152203</object-id></mixed-citation></ref>
<ref id="pone.0158770.ref044"><label>44</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Galdiero</surname> <given-names>MR</given-names></name>, <name name-style="western"><surname>Bonavita</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Barajon</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Garlanda</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Mantovani</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Jaillon</surname> <given-names>S</given-names></name>. <article-title>Tumor associated macrophages and neutrophils in cancer</article-title>. <source>Immunobiology</source>. Elsevier GmbH.; <year>2013</year>;<volume>218</volume>: <fpage>1402</fpage>–<lpage>1410</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.imbio.2013.06.003" xlink:type="simple">10.1016/j.imbio.2013.06.003</ext-link></comment> <object-id pub-id-type="pmid">23891329</object-id></mixed-citation></ref>
<ref id="pone.0158770.ref045"><label>45</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ramanathan</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Gagnon</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Ilangumaran</surname> <given-names>S</given-names></name>. <article-title>Antigen-nonspecific activation of CD8+ T lymphocytes by cytokines: relevance to immunity, autoimmunity, and cancer</article-title>. <source>Arch Immunol Ther Exp (Warsz)</source>. <year>2008</year>;<volume>56</volume>: <fpage>311</fpage>–<lpage>23</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00005-008-0033-2" xlink:type="simple">10.1007/s00005-008-0033-2</ext-link></comment></mixed-citation></ref>
<ref id="pone.0158770.ref046"><label>46</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Muranski</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Restifo</surname> <given-names>NP</given-names></name>. <article-title>Adoptive immunotherapy of cancer using CD4+ T cells</article-title>. <source>Curr Opin Immunol</source>. <year>2009</year>;<volume>21</volume>: <fpage>200</fpage>–<lpage>208</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.coi.2009.02.004" xlink:type="simple">10.1016/j.coi.2009.02.004</ext-link></comment> <object-id pub-id-type="pmid">19285848</object-id></mixed-citation></ref>
<ref id="pone.0158770.ref047"><label>47</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhang</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Eliav</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Shin</surname> <given-names>SU</given-names></name>, <name name-style="western"><surname>Schreiber</surname> <given-names>TH</given-names></name>, <name name-style="western"><surname>Podack</surname> <given-names>ER</given-names></name>, <name name-style="western"><surname>Tadmor</surname> <given-names>T</given-names></name>, <etal>et al</etal>. <article-title>B lymphocyte inhibition of anti-tumor response depends on expansion of Treg but is independent of B-cell IL-10 secretion</article-title>. <source>Cancer Immunol Immunother</source>. <year>2013</year>;<volume>62</volume>: <fpage>87</fpage>–<lpage>99</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00262-012-1313-6" xlink:type="simple">10.1007/s00262-012-1313-6</ext-link></comment> <object-id pub-id-type="pmid">22772949</object-id></mixed-citation></ref>
<ref id="pone.0158770.ref048"><label>48</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gabrilovich</surname> <given-names>DI</given-names></name>, <name name-style="western"><surname>Nagaraj</surname> <given-names>S</given-names></name>. <article-title>Myeloid-derived suppressor cells as regulators of the immune system</article-title>. <source>Nat Rev Immunol</source>. <year>2009</year>;<volume>9</volume>: <fpage>162</fpage>–<lpage>74</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nri2506" xlink:type="simple">10.1038/nri2506</ext-link></comment> <object-id pub-id-type="pmid">19197294</object-id></mixed-citation></ref>
<ref id="pone.0158770.ref049"><label>49</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Diaz-Montero</surname> <given-names>CM</given-names></name>, <name name-style="western"><surname>Salem</surname> <given-names>ML</given-names></name>, <name name-style="western"><surname>Nishimura</surname> <given-names>MI</given-names></name>, <name name-style="western"><surname>Garrett-Mayer</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Cole</surname> <given-names>DJ</given-names></name>, <name name-style="western"><surname>Montero</surname> <given-names>AJ</given-names></name>. <article-title>Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy</article-title>. <source>Cancer Immunol Immunother</source>. <year>2009</year>;<volume>58</volume>: <fpage>49</fpage>–<lpage>59</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00262-008-0523-4" xlink:type="simple">10.1007/s00262-008-0523-4</ext-link></comment> <object-id pub-id-type="pmid">18446337</object-id></mixed-citation></ref>
<ref id="pone.0158770.ref050"><label>50</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Xu</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Escamilla</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Mok</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>David</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Priceman</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>West</surname> <given-names>B</given-names></name>, <etal>et al</etal>. <article-title>CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer</article-title>. <source>Cancer Res</source>. <year>2013</year>;<volume>73</volume>: <fpage>1</fpage>–<lpage>13</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1158/0008-5472.CAN-12-3981" xlink:type="simple">10.1158/0008-5472.CAN-12-3981</ext-link></comment></mixed-citation></ref>
<ref id="pone.0158770.ref051"><label>51</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wu</surname> <given-names>C Te</given-names></name>, <name name-style="western"><surname>Hsieh</surname> <given-names>CC</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>CC</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>WC</given-names></name>, <name name-style="western"><surname>Hong</surname> <given-names>JH</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>MF</given-names></name>. <article-title>Significance of IL-6 in the transition of hormone-resistant prostate cancer and the induction of myeloid-derived suppressor cells</article-title>. <source>J Mol Med</source>. <year>2012</year>;<volume>90</volume>: <fpage>1343</fpage>–<lpage>1355</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00109-012-0916-x" xlink:type="simple">10.1007/s00109-012-0916-x</ext-link></comment> <object-id pub-id-type="pmid">22660275</object-id></mixed-citation></ref>
<ref id="pone.0158770.ref052"><label>52</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ostrand-Rosenberg</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Sinha</surname> <given-names>P</given-names></name>. <article-title>Myeloid-derived suppressor cells: linking inflammation and cancer</article-title>. <source>J Immunol</source>. <year>2009</year>;<volume>182</volume>: <fpage>4499</fpage>–<lpage>4506</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.4049/jimmunol.0802740" xlink:type="simple">10.4049/jimmunol.0802740</ext-link></comment> <object-id pub-id-type="pmid">19342621</object-id></mixed-citation></ref>
<ref id="pone.0158770.ref053"><label>53</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kim</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Bae</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Tam</surname> <given-names>M</given-names></name>. <article-title>Tumor-Associated Macrophages and Neutrophils in Tumor Microenvironment</article-title>. <year>2016</year>;<volume>2016</volume>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1155/2016/6058147" xlink:type="simple">10.1155/2016/6058147</ext-link></comment> <object-id pub-id-type="pmid">26966341</object-id></mixed-citation></ref>
<ref id="pone.0158770.ref054"><label>54</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gannon</surname> <given-names>PO</given-names></name>, <name name-style="western"><surname>Poisson</surname> <given-names>AO</given-names></name>, <name name-style="western"><surname>Delvoye</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Lapointe</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Mes-Masson</surname> <given-names>A-M</given-names></name>, <name name-style="western"><surname>Saad</surname> <given-names>F</given-names></name>. <article-title>Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients</article-title>. <source>J Immunol Methods</source>. Elsevier B.V.; <year>2009</year>;<volume>348</volume>: <fpage>9</fpage>–<lpage>17</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jim.2009.06.004" xlink:type="simple">10.1016/j.jim.2009.06.004</ext-link></comment> <object-id pub-id-type="pmid">19552894</object-id></mixed-citation></ref>
<ref id="pone.0158770.ref055"><label>55</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Flammiger</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Bayer</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Cirugeda-Kühnert</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Huland</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Tennstedt</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Simon</surname> <given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer</article-title>. <source>APMIS</source>. <year>2012</year>;<volume>120</volume>: <fpage>901</fpage>–<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1600-0463.2012.02924.x" xlink:type="simple">10.1111/j.1600-0463.2012.02924.x</ext-link></comment> <object-id pub-id-type="pmid">23009114</object-id></mixed-citation></ref>
<ref id="pone.0158770.ref056"><label>56</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ness</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Andersen</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Valkov</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Nordby</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Donnem</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Al-Saad</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Infiltration of CD8+ lymphocytes is an independent prognostic factor of biochemical failure-free survival in prostate cancer</article-title>. <source>Prostate</source>. <year>2014</year>;<volume>74</volume>: <fpage>1452</fpage>–<lpage>1461</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/pros.22862" xlink:type="simple">10.1002/pros.22862</ext-link></comment> <object-id pub-id-type="pmid">25111810</object-id></mixed-citation></ref>
<ref id="pone.0158770.ref057"><label>57</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kiniwa</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Miyahara</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>HY</given-names></name>, <name name-style="western"><surname>Peng</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Peng</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Wheeler</surname> <given-names>TM</given-names></name>, <etal>et al</etal>. <article-title>CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer</article-title>. <source>Clin Cancer Res</source>. <year>2007</year>;<volume>13</volume>: <fpage>6947</fpage>–<lpage>6958</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1158/1078-0432.CCR-07-0842" xlink:type="simple">10.1158/1078-0432.CCR-07-0842</ext-link></comment> <object-id pub-id-type="pmid">18056169</object-id></mixed-citation></ref>
<ref id="pone.0158770.ref058"><label>58</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bronte</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Kasic</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Gri</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Gallana</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Borsellino</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Marigo</surname> <given-names>I</given-names></name>, <etal>et al</etal>. <article-title>Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers</article-title>. <source>J Exp Med</source>. <year>2005</year>;<volume>201</volume>: <fpage>1257</fpage>–<lpage>1268</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1084/jem.20042028" xlink:type="simple">10.1084/jem.20042028</ext-link></comment> <object-id pub-id-type="pmid">15824085</object-id></mixed-citation></ref>
<ref id="pone.0158770.ref059"><label>59</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kawahara</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Yokomizo</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Ito</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Ito</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Ishiguro</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Teranishi</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Pretreatment neutrophil-to-lymphocyte ratio predicts the prognosis in patients with metastatic prostate cancer</article-title>. <source>BMC Cancer</source>. BMC Cancer; <year>2016</year>;<volume>16</volume>: <fpage>111</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/s12885-016-2134-3" xlink:type="simple">10.1186/s12885-016-2134-3</ext-link></comment> <object-id pub-id-type="pmid">26883640</object-id></mixed-citation></ref>
</ref-list>
</back>
</article>